StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences cash

Cash and short-term investments held at the end of each period.

Pacira BioSciences's cash was $251.03M at Jun 30, 2026. For fiscal 2025 it was $238.42M, down 50.8% from the year before. Over ten years it grew 4.3% a year on average. The highest annual figure on record is $656.41M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$238.42M-50.8%
FY2024Dec 31, 2024$484.62M+74.0%
FY2023Dec 31, 2023$278.58M-3.5%
FY2022Dec 31, 2022$288.65M-56.0%
FY2021Dec 31, 2021$656.41M+25.8%
FY2020Dec 31, 2020$521.66M+78.7%
FY2019Dec 31, 2019$291.95M-23.9%
FY2018Dec 31, 2018$383.45M+23.2%
FY2017Dec 31, 2017$311.35M+80.4%
FY2016Dec 31, 2016$172.60M+10.6%
FY2015Dec 31, 2015$156.11M-0.4%
FY2014Dec 31, 2014$156.66M+117.1%
FY2013Dec 31, 2013$72.15M+66.1%
FY2012Dec 31, 2012$43.44M-43.0%
FY2011Dec 31, 2011$76.15M+191.4%
FY2010Dec 31, 2010$26.13M+269.3%
FY2009Dec 31, 2009$7.08M-42.9%
FY2008Dec 31, 2008$12.39M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$251.03M-43.7%
Q1 FY2026Mar 31, 2026$202.18M-59.0%
Q4 FY2025Dec 31, 2025$238.42M-50.8%
Q3 FY2025Sep 30, 2025$246.33M-45.7%
Q2 FY2025Jun 30, 2025$445.86M+10.3%
Q1 FY2025Mar 31, 2025$493.63M+51.5%
Q4 FY2024Dec 31, 2024$484.62M+74.0%
Q3 FY2024Sep 30, 2024$453.81M+93.0%
Q2 FY2024Jun 30, 2024$404.23M+83.1%
Q1 FY2024Mar 31, 2024$325.89M+87.3%
Q4 FY2023Dec 31, 2023$278.58M-3.5%
Q3 FY2023Sep 30, 2023$235.19M-28.5%
Q2 FY2023Jun 30, 2023$220.77M-30.2%
Q1 FY2023Mar 31, 2023$174.00M-61.5%
Q4 FY2022Dec 31, 2022$288.65M-56.0%
Q3 FY2022Sep 30, 2022$328.73M-52.6%
Q2 FY2022Jun 30, 2022$316.39M-51.1%
Q1 FY2022Mar 31, 2022$452.19M-23.4%
Q4 FY2021Dec 31, 2021$656.41M+25.8%
Q3 FY2021Sep 30, 2021$693.86M+30.4%
Q2 FY2021Jun 30, 2021$646.60M+97.9%
Q1 FY2021Mar 31, 2021$590.06M+85.3%
Q4 FY2020Dec 31, 2020$521.66M+78.7%
Q3 FY2020Sep 30, 2020$532.13M+100.3%
Q2 FY2020Jun 30, 2020$326.79M+11.8%
Q1 FY2020Mar 31, 2020$318.46M-22.8%
Q4 FY2019Dec 31, 2019$291.95M-23.9%
Q3 FY2019Sep 30, 2019$265.64M-31.3%
Q2 FY2019Jun 30, 2019$292.24M-21.3%
Q1 FY2019Mar 31, 2019$412.44M+21.4%
Q4 FY2018Dec 31, 2018$383.45M+23.2%
Q3 FY2018Sep 30, 2018$386.41M+31.4%
Q2 FY2018Jun 30, 2018$371.32M-2.9%
Q1 FY2018Mar 31, 2018$339.79M-11.4%
Q4 FY2017Dec 31, 2017$311.35M+80.4%
Q3 FY2017Sep 30, 2017$294.08M+82.5%
Q2 FY2017Jun 30, 2017$382.44M–
Q1 FY2017Mar 31, 2017$383.70M–
Q4 FY2016Dec 31, 2016$172.60M–
Q3 FY2016Sep 30, 2016$161.13M–

More Pacira BioSciences figures

See a number that looks wrong?